

# Serum Exchange #546

**Serum 1177-1180**

The results for **Serum Exchange 546 (sera 1177 - 1180)**, are summarized in Tables 16-21 and individual laboratory results by method are listed

in Tables 22-32. Sera strongly positive to B8, A1, and A24 were examined in this study.

1177	method	#labs	B8	B7	B39	B41	B42	B45	B50	B55	B56	B59	B61	B35	B62	B71	B48	B18	B54	B67	B60	B72
	NIH-Std	4	100																			
	NIH-Ext	3	100																			
	AHG	3	100	67	33	33	33	33	33	33			33		33							
	Luminex	23	100	91	96	100	100	100	100	100	100	100	96	100	96	96	96	91	100	100	96	96
	Flow	1	no specificities assigned																			
	ELISA	2	100	100	100	100	100	100	100	100	50	100	100	100	100	100	100	100	100	50	100	100
	C1q	2	100	100								100			100							
	Other	2			50	50	50	50	50					50			50	50				
1177	method	#labs	B75	B78	B65	B64	B81	B8101	B27	B2708	B76	B82	B73	Cw7	Cw9	Cw1	Cw10	Cw8	B46	Bw6	A11	
	Luminex	23	96	91	87	78	87	22	65	35	96	87	61	65	52	48	39	22	43	26		
	ELISA	2	100	100	100	100	100	100													50	

**Sample 1177** was reported to be strongly positive to B8 by all methods. Anti -B39, -B45, -B50, and -B59 reactivity, along with reactivity to 7C and 8C specificities, was reported by various methods. In addition, Luminex reported reactivity to a number of C-locus specificities (Cw1, Cw7, Cw8, Cw9, and Cw10). Class II results for this sample were mixed. Flow, Luminex PRA, and nearly half (45%) of the Luminex labs reported this sample as negative for class II, while another 55% of the Luminex labs reported class II reactivity to DR12. Allele specific reactivity to DRB1\*12:02 was reported by 1 of the Luminex labs.

Class II						
1177	method	#labs	NEG	DR12	DQ6	DR53
	NIH-Ext	1	no specificities assigned			
	Luminex	11	55	45	18	18
	Flow	1	no specificities assigned			
	Other	2	100			

For **sample 1178**, reactivity to B8 was detected strongly by NIH-standard, NIH-extended, and C1q. By contrast, only 3 out of 23 Luminex labs reported anti-B8 reactivity. This suggests that the B8 specific antibodies present in this sample are likely IgM, as noted by several labs. Additional A-locus reactivity (A2, A23, A24, A68, and A69) was reported by various methods. Reactivity to Cw2, Cw4, and Cw12 was also reported by C1q. This sample was reported as negative for class II.

1178	method	#labs	B8	A68	A69	A2	A203	A23	A24	A2403	A28	Cw2	Cw4	Cw12	B37	B64
	NIH-Std	4	100													25
	NIH-Ext	3	67													
	AHG	3	33	33		33					33					
	Luminex	23	14	100	100	100	18	77	77	14						
	Flow	1	no specificities assigned													
	ELISA	2	50	50	50			50								
	C1q	2	100									50	50	50	100	
	Other	2		50	50	50										

Class II						
1178	method	#labs	NEG			
	NIH-Ext	1	no specificities assigned			
	Luminex	10	90			
	Flow	1	no specificities assigned			
	Other	2	100			

1179	method	#labs	A1	B8	A36	A23	A24	B18	A80	B65	B64	A34	A26	A29	B37	B59	B76	B38	B39	B42	B46		
	NIH-Std	4	80	100	20				20														
	NIH-Ext	3	100	67	33	33	33	33		33													
	AHG	3	67	33	33	67	67	67		67	33	33	33	33									
	Luminex	23	100	91	96	96	96	96	91	87	83	96	91	96	96	100	96	96	87	96	96		
	Flow	1	no specificities assigned																				
	ELISA	2	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100		100	100	100	100	
C1q	2	100	100	100	100	100	100	100	100	100	100				100	100	100						
Other	2	50	50	50	50	50	50	50															
1179	method	#labs	B54	B55	B41	B44	B45	A25	A11	B75	B78	B51	A43	A33	A68	A69	A66	A6601	B82	B67	B35	B77	
	Luminex	23	96	96	91	91	91	87	87	87	52	91	100	96	96	96	61	39	78	52	39	39	
	ELISA	2	100	100	100	100	100	100	100	100	100												

**Sample 1179** was found to be positive to A1, B8, and A36 by all methods, except flow. Additional reactivity to A26, A34, B18, B37, and B76, as well as reactivity to 1C and 8C specificities, was reported by various methods. Luminex and Elisa also detected strong anti-A11, -A25, -B39, -B44, and -B45 reactivity, including reactivity 5C and 7C specificities. Reactivity to a number of 10C specificities was also reported by Luminex. Class II reactivity to DQ2 and a number of DR specificities (DR7, DR13, DR17, DR18, and DR52) was reported by various methods. In addition, Luminex reported DP reactivity, as well as allele specific reactivity to DQA1\*05.

Class II																														
1179	method	#labs	DQ2	DR52	DR13	DR17	DR18	DR7	DQ7	DQ5	DQ4	DQ8	DQ9	DR11	DR14	DR9	DP14	DP17	DP9	DPw5	DR12	DP10	DP13	DPw1	DP19	DP28	DPw6	DR3		
	NIH-Ext	1	100																											
	Luminex	20	100	90	95	90	90	95	45	25	10	5	5	95	95	45	30	25	25	25	25	15	15	15	10	10	10	10		
	Flow	1	no specificities assigned																											
	C1q	1	100	100	100	100	100																							
	Other	2	50	50				50																						

Class II								
1180	method	#labs	DQ2	DQ7	DQ4	DQ5	DQ8	DQ9
	NIH-Ext	1	100	100				
	Luminex	19	100	95	95	95	89	89
	Flow	1	no specificities assigned					
	C1q	1	100	100	100	100	100	100
	Other	2	50	50	50	50	50	50

For **sample 1180**, strong reactivity to A1, A24, and B8 was reported by all methods. Additional reactivity to a number of 1C and 5C specificities, along with anti-B54, -B56, and -B59 reactivity, was reported by various methods. Class II reactivity to DQ2 and DQ7 was reported by Luminex, 1 NIH-extended lab, and 1 C1q lab. Additional DQ reactivity (DQ4, DQ5, DQ8, and DQ9) was also reported by Luminex and C1q.

1180	method	#labs	A24	B8	A1	A23	A36	A11	A1102	A3	B62	A80	B59	B35	B46	B56	B50	B51	B53	B54	B72	B75
	NIH-Std	4	100	100	50	25																
	NIH-Ext	3	100	100	67																	
	AHG	3	100	67	100	67	67	33		33	33			33								
	Luminex	23	95	91	100	95	95	83	30	95	91	83	100	91	100	95	91	91	91	91	91	91
	Flow	1	no specificities assigned																			
	ELISA	2	100	100	100	100	100	100		100	100	100	100	100	100	100	100	100	100	100	50	100
	C1q	2	100	100	100	100	100	100		100	100	100	100									
Other	2	50	50	50	50	50	50		50		50											
1180	method	#labs	B49	B63	B71	B76	B78	B18	B64	B65	B77	B52	A68	A69	A2	B48	B68	B57	B41	B55	B45	
	Luminex	23	83	83	83	78	78	65	48	70	91	83	91	78	74	61	61	48	48	43	39	
	ELISA	2	100	100	100	100	100	50	50													

**Table 16. Summary of the 546<sup>th</sup> Serum Exchange (Serum #1177-1180) by NIH-Standard and NIH-Extended - class I**

<b>Method: NIH-Standard</b>											
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>		
4 typing Labs			4 typing Labs			5 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B8	100%	65%	B8	100%	87%	B8	100%	97%	A24	100%	94%
			B64	25%	50%	A1	80%	100%	B8	100%	80%
						A36	20%	100%	A1	50%	100%
						A80	20%	100%	A23	25%	100%

<b>Method: NIH-Extended</b>											
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B8	100%	75%	B8	100%	100%	A1	100%	100%	A24	100%	90%
						B8	67%	100%	B8	100%	75%
						A23	33%	100%	A1	67%	75%
						A24	33%	100%			
						A36	33%	100%			
						B18	33%	100%			
						B65	33%	100%			

**Table 17. Summary of the 546<sup>th</sup> Serum Exchange (Serum #1177-1180) by Antiglobuline, C1q, and Other - class I**

Method: Antiglobulin											
*** Serum 1177 ***			*** Serum 1178 ***			*** Serum 1179 ***			*** Serum 1180 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B8	100%	100%	A2	33%	100%	A1	67%	100%	A1	100%	100%
B7	67%	75%	A28	33%	100%	A23	67%	100%	A24	100%	96%
B39	33%	100%	A68	33%	100%	A24	67%	100%	A23	67%	100%
B41	33%	100%	B8	33%	100%	B18	67%	100%	B8	67%	100%
B42	33%	100%				B65	67%	86%	A36	67%	67%
B45	33%	100%				A26	33%	100%	A11	33%	100%
B50	33%	100%				A29	33%	100%	B35	33%	100%
B55	33%	100%				A34	33%	100%	B62	33%	100%
B56	33%	100%				A36	33%	100%	A3	33%	90%
B61	33%	100%				B64	33%	100%			
B62	33%	100%				B8	33%	100%			

Method: C1q											
*** Serum 1177 ***			*** Serum 1178 ***			*** Serum 1179 ***			*** Serum 1180 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B59	100%	100%	B8	100%	100%	A1	100%	100%	A1	100%	100%
B7	100%	100%	Cw12	50%	100%	A23	100%	100%	A11	100%	100%
B71	100%	100%	Cw2	50%	100%	A24	100%	100%	A23	100%	100%
B8	100%	100%	Cw4	50%	100%	A36	100%	100%	A24	100%	100%
						A80	100%	100%	A3	100%	100%
						B18	100%	100%	A36	100%	100%
						B37	100%	100%	A80	100%	100%
						B59	100%	100%	B59	100%	100%
						B64	100%	100%	B62	100%	100%
						B65	100%	100%	B76	100%	100%
						B76	100%	100%	B8	100%	100%
						B8	100%	100%			

Method: Other											
*** Serum 1177 ***			*** Serum 1178 ***			*** Serum 1179 ***			*** Serum 1180 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

**Table 18. Summary of the 546<sup>th</sup> Serum Exchange (Serum #1177-1180) by Luminex - class I**

*** Serum 1177 ***		
23 typing Labs		
Antigen	Consensus	Inclusion
B35	100%	100%
B41	100%	100%
B42	100%	100%
B45	100%	100%
B54	100%	100%
B55	100%	100%
B56	100%	100%
B59	100%	100%
B67	100%	100%
B8	100%	100%
B50	100%	80%
B39	96%	100%
B60	96%	100%
B61	96%	100%
B62	96%	100%
B71	96%	100%
B72	96%	100%
B75	96%	100%
B76	96%	100%
B48	96%	80%
B18	91%	100%
B7	91%	100%
B78	91%	80%
B82	87%	100%
B65	87%	80%
B81	87%	80%
B64	78%	100%
B27	65%	67%
CW7	65%	100%
B73	61%	100%
CW9	52%	100%
CW1	48%	100%
B46	43%	100%
CW10	39%	100%
B2708	35%	100%
BW6	26%	100%
B8101	22%	100%
CW8	22%	100%

*** Serum 1178 ***		
22 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
A69	100%	100%
A68	100%	92%
A23	77%	100%
A24	77%	83%
A203	18%	100%
A2403	14%	100%
B8	14%	100%

*** Serum 1179 ***		
23 typing Labs		
Antigen	Consensus	Inclusion
A1	100%	100%
A43	100%	100%
B59	100%	100%
A23	96%	100%
A29	96%	100%
A33	96%	100%
A34	96%	100%
A36	96%	100%
A68	96%	100%
A69	96%	100%
B18	96%	100%
B37	96%	100%
B38	96%	100%
B42	96%	100%
B46	96%	100%
B54	96%	100%
B55	96%	100%
B76	96%	100%
A24	96%	86%
A26	91%	100%
A80	91%	100%
B41	91%	100%
B45	91%	100%
B8	91%	100%
B44	91%	88%
B51	91%	67%
A25	87%	100%
B39	87%	100%
B65	87%	100%
B75	87%	100%
A11	83%	100%
B64	83%	100%
B82	78%	100%
A66	61%	50%
B67	52%	100%
B78	52%	100%
A6601	39%	100%
B35	39%	100%
B77	39%	100%

*** Serum 1180 ***		
22 typing Labs		
Antigen	Consensus	Inclusion
A1	100%	100%
B46	100%	100%
B59	100%	100%
A23	95%	100%
A3	95%	100%
A36	95%	100%
B56	95%	100%
A24	95%	93%
B35	91%	100%
B50	91%	100%
B51	91%	100%
B53	91%	100%
B54	91%	100%
B62	91%	100%
B72	91%	100%
B77	91%	100%
B8	91%	100%
B75	91%	88%
A68	91%	75%
A11	83%	100%
A80	83%	100%
B49	83%	100%
B52	83%	100%
B63	83%	100%
B71	83%	100%
B76	78%	100%
B78	78%	100%
A69	78%	75%
A2	74%	89%
B65	70%	100%
B18	65%	80%
B48	61%	100%
B58	61%	33%
B41	48%	100%
B57	48%	100%
B64	48%	100%
B55	43%	100%
B45	39%	100%
A1102	30%	100%

**Table 19. Summary of the 546<sup>th</sup> Serum Exchange (Serum #1177-1180) by Flow Cytometry and ELISA - class I**

Method: Flow Cytometry											
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>		
1 typing Labs			1 typing Labs			1 typing Labs			1 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: ELISA											
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B18	100%	100%	B37	100%	100%	A1	100%	100%	A1	100%	100%
B35	100%	100%	A23	50%	100%	A23	100%	100%	A11	100%	100%
B39	100%	100%	A68	50%	100%	A29	100%	100%	A23	100%	100%
B41	100%	100%	A69	50%	100%	A36	100%	100%	A24	100%	100%
B42	100%	100%	B8	50%	100%	A80	100%	100%	A3	100%	100%
B45	100%	100%				B18	100%	100%	A36	100%	100%
B48	100%	100%				B37	100%	100%	A80	100%	100%
B50	100%	100%				B38	100%	100%	B35	100%	100%
B54	100%	100%				B39	100%	100%	B46	100%	100%
B55	100%	100%				B41	100%	100%	B49	100%	100%
B59	100%	100%				B42	100%	100%	B50	100%	100%
B60	100%	100%				B46	100%	100%	B53	100%	100%
B61	100%	100%				B54	100%	100%	B56	100%	100%
B62	100%	100%				B55	100%	100%	B59	100%	100%
B64	100%	100%				B59	100%	100%	B62	100%	100%
B65	100%	100%				B64	100%	100%	B63	100%	100%
B7	100%	100%				B65	100%	100%	B71	100%	100%
B71	100%	100%				B78	100%	100%	B72	100%	100%
B72	100%	100%				B8	100%	100%	B75	100%	100%
B75	100%	100%				A26	100%	75%	B78	100%	100%
B78	100%	100%				B45	100%	75%	B8	100%	100%
B8	100%	100%				A24	100%	50%	B51	100%	50%
B81	100%	100%				A25	50%	100%	B54	50%	100%
B27	100%	50%				A34	50%	100%	B18	50%	50%
B56	50%	100%				B75	50%	100%	B64	50%	50%
B67	50%	100%				A11	50%	50%			
A11	50%	50%				B44	50%	50%			

**Table 20. Summary of the 546<sup>th</sup> Serum Exchange (Serum #1177-1180) by NIH-Ext, Flow, C1q, and Other - class II**

Method: NIH-Extended												
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>			
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab			
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	
no consensus			no consensus			no consensus			no consensus			

Method: Flow Cytometry												
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>			
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab			
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	
no antigens assigned			no antigens assigned			no consensus			no consensus			

Method: C1q												
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>			
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab			
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	
no antigens assigned			no antigens assigned			no consensus			no consensus			

Method: Other												
<b>*** Serum 1177 ***</b>			<b>*** Serum 1178 ***</b>			<b>*** Serum 1179 ***</b>			<b>*** Serum 1180 ***</b>			
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs			
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	
no antigens assigned			no antigens assigned			DQ2	50%	100%	DQ2	50%	100%	
						DR52	50%	100%	DQ4	50%	100%	
						DR7	50%	100%	DQ5	50%	100%	
									DQ7	50%	100%	
									DQ8	50%	100%	
									DQ9	50%	100%	

**Table 21. Summary of the 546<sup>th</sup> Serum Exchange (Serum #1177-1180) by Luminex- class II**

*** Serum 1177 ***		
11 typing Labs		
Antigen	Consensus	Inclusion
DR12	45%	75%
DQ6	18%	100%
DR53	18%	100%
DQ5	9%	100%
DR10	9%	100%
DR15	9%	100%
DR16	9%	100%
DPW1	9%	50%
DR14	9%	50%
DR51	9%	50%
DR9	9%	50%

*** Serum 1178 ***		
10 typing Labs		
Antigen	Consensus	Inclusion
no antigens assigned		

*** Serum 1179 ***		
20 typing Labs		
Antigen	Consensus	Inclusion
DQ2	100%	100%
DR11	95%	100%
DR13	95%	100%
DR14	95%	100%
DR7	95%	100%
DR17	90%	100%
DR18	90%	100%
DR52	90%	100%
DQ7	45%	80%
DR9	45%	50%
DP14	30%	100%
DP17	25%	100%
DP9	25%	100%
DPW5	25%	100%
DQ5	25%	100%
DR12	25%	100%
DP10	15%	100%
DP13	15%	100%
DPW1	15%	100%
DP19	10%	100%
DP28	10%	100%
DPW6	10%	100%
DR3	10%	100%
DQ4	10%	75%
DPW3	5%	100%
DPW4	5%	100%
DQ8	5%	67%
DQ9	5%	67%

*** Serum 1180 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DQ2	100%	100%
DQ4	95%	82%
DQ7	95%	82%
DQ5	95%	72%
DQ9	89%	90%
DQ8	89%	88%
DQ1	5%	100%
DQ3	5%	100%
DQ6	5%	100%
DR11	5%	100%
DR13	5%	100%
DR14	5%	100%
DR17	5%	100%
DR18	5%	100%
DR52	5%	100%
DR7	5%	100%



**Table 22. Individual laboratory results for Serum #1177-#1180 by NIH-Standard and NIH-Extended**

	**** Serum 1177 ****			**** Serum 1178 ****				**** Serum 1179 ****						**** Serum 1180 ****						
Investigator	% POS	B8	Other	% POS	B8	B64	Other	% POS	B8	A1	A36	A80	Other	% POS	A24	B8	A1	A23	Other	Method
Claas, F.H.J.	25	+		21	+			42	+	+	+			54	+	+	+			STD
Fort, Marylise								14	+	+		+		NT						STD
Thornton, Alycia		+			+				+						+	+				STD
Vasilescu, Rodica	6	+		5	+			17	+	+				22	+	+	+	+		STD
Watson, Narelle	21	+		28	+	+		39	+	+				40	+	+				STD

	**** Serum 1177 ****			**** Serum 1178 ****				**** Serum 1179 ****						**** Serum 1180 ****						
Investigator	% POS	B8	Other	% POS	B8		Other	% POS	A1	B8			Other	% POS	A24	B8	A1		Other	Method
Dunn, Paul		+			+				+	+			A24,A23,B65,B18		+	+	+			EXT
Lardy, N.M.	12	+		23	+			35	+	+			A36	40	+	+	+			EXT
Reed, Elaine F. PhD	3	+		3	+			20	+					20	+	+				EXT

**Table 23. Individual laboratory results for Serum #1177-#1180 by Antiglobulin, C1q, and Other**

Investigator	**** Serum 1177 ****										**** Serum 1178 ****					**** Serum 1179 ****										**** Serum 1180 ****										Other	Method									
	% POS	B8	B7	B39	B41	B42	B45	B50	B55	Other	% POS	B8	A2	A28	A68	Other	% POS	A1	A23	A24	B18	B65	A26	A29	A66	A34	A36	B37	B13	Other	% POS	A1	A24	A23	B8			A36	A11	A3	B35	B62				
Cecka, J. Michael P	82	+	+	+	+	+	+	+	+	B60>	47		+	+	+		80	+	+	+	+	+	+	+	+	+	+		B64	72	+	+	+		+	+	+	+	+							AHG
Hahn, Amy B. PhD		+	+																			+						+	+	B35>		+	+		+	+									AHG	
Vasilescu, Rodica	10	+									6	+					30	+	+	+	+								B8	22	+	+	+	+											AHG	

AHG=Antiglobulin

Investigator	**** Serum 1177 ****										**** Serum 1178 ****					**** Serum 1179 ****										**** Serum 1180 ****										Other	Method										
	% POS	B8	B7	B71	B59					Other	% POS	B8				Other	% POS	A1	A23	A24	A36	A80	B18	B8	B37	B59	B64	B65	B76	Other	% POS	A1	A23	A24	B8			A36	A11	A3	A80	B59	B62	B76			
Phelan, Donna L.		+	+	+	+							+						+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	C1q	
Vasilescu, Rodica		+	+	+	+							+			CW4>			+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	C1q

Investigator	**** Serum 1177 ****										**** Serum 1178 ****					**** Serum 1179 ****										**** Serum 1180 ****										Other	Method											
	% POS	B18	B35	B39	B41	B42	B45	B48	B50	Other	% POS	A2	A68	A69	Other	% POS	A1	A23	A24	A36	A80	B18	B8							Other	% POS	A1	A23	A24	B8			A36	A11	A3	A80							
Phelan, Donna L.	87										44					89														89																	Other	
Reed, Elaine F. PhD	88	+	+	+	+	+	+	+	+	B60>	52	+	+	+		90	+	+	+	+	+	+	+							88	+	+	+	+	+	+	+	+										Other

Other=Luminex PRA

**Table 24. Individual laboratory results for Serum #1177 by Luminex**

		**** Serum 1177 ****																																												
Investigator	% POS	B35	B41	B42	B45	B54	B55	B56	B59	B67	B8	B50	B39	B60	B61	B62	B71	B72	B75	B76	B48	B18	B7	B78	B82	B65	B81	B64	B27	CW7	B73	CW9	CW1	B46	CW10	B2708	BW6	Other	Method							
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+												+	B8101,B7801,B8201>	LMX			
Bengochea, Carrette	32	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																	+	B14,B8101	LMX		
Cecka, J. Michael PhD	47	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																LMX	
Chen, Dong-Feng PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,B7801,B8201	LMX		
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,CW8	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+									+	+		LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B63,CW8,CW14,CW16	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Hamdi, Nuha	87	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B13,B47,B77	LMX			
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW8,CW14,CW16	LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+													+	B14	LMX		
Libyh/Roulin, Tabary	53	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B63,B8101,B7801>	LMX		
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B13,B77	LMX	
McCoy, Heather	32	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pancoska, Carol PhD	37	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pule, Ziningi	32	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B40,B15,B14	LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Rosen-Bronson, Sari		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B703	LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW8	LMX	
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW8,CW14,CW16	LMX

**Table 25. Individual laboratory results for Serum #1178 by Luminex**

**** Serum 1178 ****											
Investigator	% POS	A2	A69	A68	A23	A24	A203	A2403	B8	Other	Method
Arnold, Paula PhD		+	+	+			+				LMX
Bengochea, Carretto	11	+	+	+	+	+			+		LMX
Cecka, J. Michael P	40	+	+	+							LMX
Chen, Dong-Feng P		+	+	+	+	+		+			LMX
Dunn, Paul		+	+	+	+	+	+	+			LMX
Eckels/CPMC,		+	+	+							LMX
Fort, Marylise		+	+	+	+	+				B76	LMX
Hahn, Amy B. PhD		+	+	+	+	+				A2C	LMX
Hamdi, Nuha	38	+	+	+	+	+				A74	LMX
Holdsworth, Rhonda		+	+	+	+	+					LMX
Lardy, N.M.		+	+	+							LMX
Libyh/Roulin, Tabary	31	+	+	+	+	+	+	+		B76	LMX
Martinho, Paiva &		+	+	+	+	+				A74	LMX
McCoy, Heather	9	+	+	+	+	+					LMX
Pancoska, Carol Ph	9	+	+	+	+	+					LMX
Permpikul, Vejbaesy		+	+	+	+	+					LMX
Phelan, Donna L.											LMX
Pule, Ziningi	29	+	+	+	+	+			+	B15,B48,B13,B57 >	LMX
Reed, Elaine F. PhD		+	+	+							LMX
Rosen-Bronson, Sai		+	+	+	+	+					LMX
Thornton, Alycia		+	+	+	+	+	+				LMX
Vasilescu, Rodica		+	+	+	+	+					LMX
Vather, Kuben		+	+	+	+	+			+	B57	LMX

**Table 26. Individual laboratory results for Serum #1179 by Luminex**

		**** Serum 1179 ****																																						
Investigator	% POS	A1	A43	B59	A23	A29	A33	A34	A36	A68	A69	B18	B37	B38	B42	B46	B54	B55	B76	A24	A26	A80	B41	B45	B8	B44	B51	A25	B39	B65	B75	A11	B64	B82	A66	B67	B78	Other	Method	
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A1101,A1102,B39	LMX	
Bengochea, Carretto	41	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B7801,A6601	LMX	
Cecka, J. Michael PhD	75	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Chen, Dong-Feng PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B53,A30,B77,B35	LMX	
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B53,A30,B77,B35	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A6601	LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A30,B77,B35	LMX	
Hamdi, Nuha	58	+	+	+								+							+	+							+		+	+							B49,B50,B13,B53	LMX		
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B53,A30,B77	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+			+							+			B14	LMX
Libyh/Roulin, Tabary	84	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		B7801,A1101,A11	LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+			+	+		+	+	+	+	+	+	+	+	+	+	+		B62,B13,B27,B53	LMX
McCoy, Heather	42	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pancoska, Carol PhD	54	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pule, Ziningi	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B15,B14	LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A6601,A*24:02	LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B53,A30,B77	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A1101,A1102	LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B53,A30,B77,B35	LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B62,B53,A30,B77	LMX

**Table 27. Individual laboratory results for Serum #1180 by Luminex**

		**** Serum 1180 ****																																											
Investigator	% POS	A1	B46	B59	A23	A3	A36	B56	A24	B35	B50	B51	B53	B54	B62	B72	B77	B8	B75	A68	A11	A80	B49	B52	B63	B71	B76	B78	A69	A2	B65	B18	B48	B58	B41	B57	B64	B55	Other	Method					
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+														A2403,B7801,A1101>	LMX		
Bengochea, Carrette	38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+													A2403,A1101,A1102	LMX	
Cecka, J. Michael P	80	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+											LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A2403,B7801,A1101>	LMX	
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B45,A2403,A1101,A1102	LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Fort, Marylise																																												LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B45	LMX	
Hamdi, Nuha	89	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B13,B44,B27 >	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B45,B39,B42	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Libyh/Roulin, Tabary	78	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B45,A2403,B7801 >	LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B13,B7,B45,A43 >	LMX	
McCoy, Heather	36	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pancoska, Carol Ph	48	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pule, Ziningi	37	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B15	LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B45,B39	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2403,A1102	LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B45,A2403,A1102 >	LMX	
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B45,B39	LMX	

**Table 28. Individual laboratory results for Serum #1177-#1180 by ELISA and Flow Cytometry**

		**** Serum 1177 ****																										**** Serum 1178 ****																										
Investigator	% POS	B18	B35	B39	B41	B42	B45	B48	B50	B54	B55	B59	B60	B61	B62	B64	B65	B7	B71	B72	B75	B78	B8	B81	B27	Other	% POS	B37	A23	A68	A69	B8																					Other	Method
Hahn, Amy B. PhD	6	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11>		+	+																				Elisa					
McCoy, Heather	6	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B67	5	+		+	+	+																		Elisa				
Eckels/CPMC, FC=Flow Cytometry	87																										53																								FC			

  

		**** Serum 1179 ****																										**** Serum 1180 ****																								
Investigator	% POS	A1	A23	A29	A36	A80	B18	B37	B38	B39	B41	B42	B46	B54	B55	B59	B64	B65	B78	B8	A26	B45	A24	Other	% POS	A1	A11	A23	A24	A3	A36	A80	B35	B46	B49	B50	B53	B56	B59	B62	B63	B71	B72	B75	B78	B8	B51	Other	Method			
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		A11>		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		Elisa	
McCoy, Heather	28	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		B44>	11	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B54>	Elisa		
Eckels/CPMC,	96																								96																											FC

**Table 29. Individual laboratory results for Serum #1177-#1180 by Luminex - class II**

Investigator	**** Serum 1177 ****					**** Serum 1178 ****		**** Serum 1179 ****																	**** Serum 1180 ****								Method							
	% POS	DR12	DQ6	DR53	Other	% POS	no antigens assigned	% POS	DQ2	DR11	DR13	DR14	DR7	DR17	DR18	DR52	DQ7	DR9	DP14	DP17	DP9	DPw5	DQ5	DR12	DP10	DP13	DPw1	Other	% POS	DQ2	DQ4	DQ5		DQ7	DQ9	DQ8	Other			
Arnold, Paula PhD	0					0			+	+	+	+	+	+	+	+	+																							LMX
Bengochea, Carrette								38	+	+	+	+	+			+	+	+	+	+		+					+	+										DQ1,DQ6	LMX	
Cecka, J. Michael PI	0					0		80	+	+	+	+	+	+	+	+																							LMX	
Chen, Dong-Feng P									+	+	+	+	+	+	+	+																							LMX	
Dunn, Paul		+							+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																	LMX
Eckels/CPMC,									+	+	+	+	+	+	+	+	+																							LMX
Fort, Marylise									+	+	+	+	+	+	+	+	+																							LMX
Hahn, Amy B. PhD		+							+	+	+	+	+	+	+	+	+																							LMX
Hamdi, Nuha	0	+	+	+	DR9,DR10>	0		71	+								+																						LMX	
Holdsworth, Rhonda					DRB1*12:02	0			+	+	+	+	+	+	+	+	+	+	+		+	+																		LMX
Libyh/Roulin, Tabary	0					0		83	+	+	+	+	+	+	+	+																								LMX
Pancoska, Carol Ph	0					0		38	+	+	+	+	+	+	+	+	+																							LMX
Perpikul, Vejbaesy									+	+	+	+	+	+	+	+	+																							LMX
Phelan, Donna L.									+	+	+	+	+	+	+	+	+																							LMX
Pule, Ziningi	1		+			1		40	+	+	+	+	+	+	+	+									+														DQ3	LMX
Reed, Elaine F. PhD	0					0			+	+	+	+	+	+	+	+																								LMX
Rosen-Bronson, Sar						0			+	+	+	+	+	+	+	+					+																			LMX
Thornton, Alycia									+	+	+	+	+	+	+	+			+	+	+							+												LMX
Vather, Kuben		+		+		0			+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+														LMX
Vather, Nelson/		+							+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+												LMX



**Table 30. Individual laboratory results for Serum #1177-#1180 by Flow Cytometry, NIH-Extended, Other, and C1q - class II**

Investigator	**** Serum 1177 ****		**** Serum 1178 ****		**** Serum 1179 ****							**** Serum 1180 ****							Method		
	% POS	no antigens assigned	% POS	no antigens assigned	% POS	DQ2	DR52	DR7	DR13	DR17	DR18	Other	% POS	DQ2	DQ4	DQ7	DQ5	DQ8		DQ9	Other
Eckels/CPMC,	0		0		83								96								FC
Reed, Elaine F. PhD	15		11		74	+							32	+		+					EXT
Reed, Elaine F. PhD	0		0		63	+	+	+					93	+	+	+	+	+	+		Other
Phelan, Donna L.	0		0		86								83								Other
Phelan, Donna L.						+	+		+	+	+			+	+	+	+	+	+		C1q

**NEXT MAILING DATE: November 4, 2015**  
*Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed*